Timetable: Marketing authorisation renewal application - ATMP
Submitted by Anonymous (not verified) on 28 May 2026 - 14:25
Timetable: Marketing authorisation renewal application - ATMP
Timetable: Marketing authorisation renewal application
Submitted by Anonymous (not verified) on 28 May 2026 - 14:20
Timetable: Marketing authorisation renewal application
Human medicines European public assessment report (EPAR): Beromun, tasonermin, Date of authorisation: 12/04/1999, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 28 May 2026 - 12:46
Human medicines European public assessment report (EPAR): Beromun, tasonermin, Date of authorisation: 12/04/1999, Revision: 16, Status: Authorised
PSUSA/00002478/202508
Submitted by Anonymous (not verified) on 28 May 2026 - 12:18
PSUSA/00002478/202508
Clinical pharmacology and pharmacokinetics: questions and answers
Submitted by Anonymous (not verified) on 28 May 2026 - 9:55
Clinical pharmacology and pharmacokinetics: questions and answers
Podcast: Inside EMA
Submitted by Anonymous (not verified) on 28 May 2026 - 9:35
Podcast: Inside EMA
PSUSA/00001819/202509
Submitted by Anonymous (not verified) on 27 May 2026 - 15:18
PSUSA/00001819/202509
European Medicines Agency (EMA) / European Chemicals Agency (ECHA) joint meeting with industry stakeholders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 9 June 2026, 09:00 (CEST) to 9 June 2026, 12:00 (CEST)
Submitted by Anonymous (not verified) on 27 May 2026 - 15:12
European Medicines Agency (EMA) / European Chemicals Agency (ECHA) joint meeting with industry stakeholders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 9 June 2026, 09:00 (CEST) to 9 June 2026, 12:00 (CEST)
Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 12, Status: Authorised
Submitted by Anonymous (not verified) on 27 May 2026 - 15:02
Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 12, Status: Authorised
Accelerating Clinical Trials in the EU (ACT EU)
Submitted by Anonymous (not verified) on 27 May 2026 - 15:00
Accelerating Clinical Trials in the EU (ACT EU)